$560.38
1.13%
Nasdaq, Oct 23, 04:06 pm EDT. Closed.
ISIN
US45168D1046
Symbol
IDXX

IDEXX Laboratories Target price 2026 - Analyst rating & recommendation

IDEXX Laboratories Classifications & Recommendation

Buy
64%
Hold
36%

IDEXX Laboratories Price Target

Target Price $724.20
Price $560.38
Potential 29.23%
Number of Estimates 16
16 Analysts have issued a price target IDEXX Laboratories 2027 . The average IDEXX Laboratories target price is $724.20. This is 29.23% higher than the current stock price. The highest price target is $845.25 50.84% , the lowest is $477.17 14.85% .
A rating was issued by 22 analysts: 14 Analysts recommend IDEXX Laboratories to buy, 8 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the IDEXX Laboratories stock has an average upside potential 2027 of 29.23% . Most analysts recommend the IDEXX Laboratories stock at Purchase.

Sales and Margin forecast 2026, 2027 to 2033

Sign up for free to unlock analyst estimates. Sign up for free

Select at least one metric to display the chart.


Dec '25 2026
Estimates
Revenue Billion $ ??? ???
??? ???
EBITDA Margin ??? ???
??? ???
Net Margin ??? ???
??? ???

19 Analysts have issued a sales forecast IDEXX Laboratories 2026 . The average IDEXX Laboratories sales estimate is

. This is than the revenue of the last 12 months(TTM). The highest sales forecast is , the lowest is .

This results in the following potential growth metrics:

Revenue Estimates

2025 $4.3b 10.42%
2026
2027
2028
2029
2030
2031
2032
2033

16 Analysts have issued an IDEXX Laboratories EBITDA forecast 2026. The average IDEXX Laboratories EBITDA estimate is

. This is than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is , the lowest is .

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2025 $1.5b 19.53%
2026
2027
2028
2029
2030
2031
2032
2033

EBITDA Margin

2025 35.07% 8.25%
2026
2027
2028
2029
2030
2031
2032
2033

18 IDEXX Laboratories Analysts have issued a net profit forecast 2026. The average IDEXX Laboratories net profit estimate is

. This is than the net profit for the last 12 months(TTM). The highest net profit forecast is , the lowest is .

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2025 $1.1b 19.33%
2026
2027
2028
2029
2030
2031
2032
2033

Net Margin

2025 24.62% 8.06%
2026
2027
2028
2029
2030
2031
2032
2033

Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2033

Sign up for free to unlock analyst estimates. Sign up for free

Select at least one metric to display the chart.


Dec '25 2026
Estimates
Earnings Per Share $ ??? ???
??? ???
P/E ???
EV/Sales ???

18 Analysts have issued a IDEXX Laboratories forecast for earnings per share. The average IDEXX Laboratories EPS is

. This is than earnings per share in the financial year 2025. The highest EPS forecast is , the lowest is .

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2025 $13.08 22.59%
2026
2027
2028
2029
2030
2031
2032
2033

P/E ratio

Current 39.02 25.32%
2026
2027
2028
2029
2030
2031
2032
2033

Based on analysts' sales estimates for 2026, the IDEXX Laboratories stock is valued at an EV/Sales of

and an P/S ratio of .

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 9.87 23.01%
2026
2027
2028
2029
2030
2031
2032
2033

P/S ratio

Current 9.70 22.99%
2026
2027
2028
2029
2030
2031
2032
2033

Current IDEXX Laboratories Upgrades & Downgrades

Analyst Rating Action Date
JP Morgan
Overweight
➜
Overweight
Unchanged Oct 16 2026
Keybanc
➜
Sector Weight
Initiated Oct 12 2026
Barclays
Overweight
➜
Overweight
Unchanged Aug 11 2026
Citigroup
Neutral
➜
Neutral
Unchanged Aug 05 2026
UBS
Neutral
➜
Neutral
Unchanged Aug 05 2026
UBS
Neutral
➜
Neutral
Unchanged Jul 27 2026
UBS
Neutral
➜
Neutral
Unchanged Apr 28 2026
Analyst Rating Date
Unchanged
JP Morgan:
Overweight
➜
Overweight
Oct 16 2026
Initiated
Keybanc:
➜
Sector Weight
Oct 12 2026
Unchanged
Barclays:
Overweight
➜
Overweight
Aug 11 2026
Unchanged
Citigroup:
Neutral
➜
Neutral
Aug 05 2026
Unchanged
UBS:
Neutral
➜
Neutral
Aug 05 2026
Unchanged
UBS:
Neutral
➜
Neutral
Jul 27 2026
Unchanged
UBS:
Neutral
➜
Neutral
Apr 28 2026

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today